Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Request Sample

CAR-T Cell Therapy Market – A Revolution in Cancer Treatment

In the recent past, cancer therapy such as targeted immunotherapies that includes CAR-T cell therapies is been preferred over surgery, chemotherapy, and radiation. These target cancer cells and strengthen the patient’s immune system against the tumor. CAR-T cell therapy is a type of treatment in which T-cells derived from patient’s blood are modified in laboratory with the addition of a special protein receptor on the T-cells that attack cancer cells. This special receptor is known as Chimeric Antigen Receptor (CAR) that binds to specific protein on patient’s cancer cells. Millions of CAR-T cells are grown in the laboratory and then administered in the patients through infusion. These cells bind to the infected cancer cells and have the ability to kill them thereby leading to curing of the cancer. Masking of cancer cells from immune cells can be combated by the incorporation of immune checkpoint inhibitors in body which can detect and inhibit cancer cells. This innovative approach of using the body’s immune cells to target cancer causing cells has been successful used in the treatment of pediatric relapsed acute lymphoblastic leukemia, refractory non-Hodgkin lymphoma, and other cancers.

The global CAR-T Cell therapy market is estimated to be valued at US$ 295.1 million in 2018 and is expected to witness a CAGR of 32.5 % over the forecast period (2018 – 2028).

Figure 1. North America CAR-T Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth, 2018–2028

Source: Coherent Market insights (2018)

Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the global CAR-T cell therapy market. Rising number of adults and children developing cancer is expected to lead to high demand for an effective and reliable therapeutic treatment approach for improvement of quality of patient’s lives. The Cancer Research UK reported that over 14.1 million cancer cases occurred in 2012 across the world. Moreover, according to the Leukemia and Lymphoma Society of Canada, around 22,340 people in Canada were diagnosed with some form of blood cancer, of which 9,000 cases were lymphoma.

Moreover, development of new and effective therapy options to cure symptoms of the disease is also a vital factor contributing to growth of CAR-T cell therapy market. In 2017, the U.S. Food and Drug Administration approved two CAR-T cell therapies Kymriah and Yescarta for children and adult lymphoblastic leukemia and advanced lymphoma in adults, respectively. This is expected to aid in growth of the market over the forecast period.

Furthermore, increasing government initiatives for improving health care infrastructure and promoting research for cell therapy in cancer is fueling growth of the market. For instance, in December 2016, the National Cancer Advisory Board authorized US$ 1.8 Bn in funding for Cancer Moonshot, which is an initiative taken up to accelerate research with an aim to make more therapies available to patients with cancer.

However, side effects associated with the cell therapy may lead to cytokine release syndrome (CRS) and other neurological problems that include seizures, coma, hallucinations, and delirium. This factor is expected to hinder the market growth.

In terms of market size, North America is dominant in the global CAR-T cell therapy market. This is attributed to rapid development and launch of new therapies for the treatment of cancer by key players in the market in the region. For instance, in August 2017, the U.S. Food and Drug Administration (FDA) approved Kymriah, a CAR-T cell therapy to treat pediatric and young adult patients suffering with a form of acute lymphoblastic leukemia. Moreover, a large patient pool suffering from cancer in the U.S. and Canada is expected to further support growth of region in the global market. For instance, according to the Centers of Disease Control and Prevention (CDC) 2016, around 171,000 patients with blood cancer are diagnosed each year in the U.S. Europe is expected to be the second most prominent market, in terms of revenue, owing to rising investment and extensive research for development of cancer therapies in the region. For instance, the European Hematology and Oncology department published an undergoing study in 2017 that states the role of CAR-T cells in treatment of Leukapheresis. Furthermore, Asia Pacific is expected to exhibit highest growth over the forecast period, owing to increasing number of global players collaborating and signing research as well as manufacturing contracts for CAR-T cell therapies with local players in the region. For instance, Cesca Therapeutics signed a license agreement with China-based, Boyalife Group, in March 2018, for CAR-T cell related bioprocessing, development, and manufacturing outsourcing.

Market players are engaged in developing and launching innovative products and adopt merger and acquisition strategies to retain position in the global CAR-T cell therapy market

Key players in the market are engaged in extensive research and development to launch new targeted cell therapies in the market. For instance, the University of Texas MD Anderson Cancer Center, Houston is conducting phase 1 clinical trial studies of central memory–derived CD19 CAR T–cell therapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma. Moreover, key players are focusing on strategic merger and acquisition to enhance their share in the global CAR-T cell therapy market. For instance, in April 2018, Pfizer, Inc. signed a deal with Allogene, to develop an investigational CAR-T cell therapy for treating cancer.

Key players operating in the global CAR-T cell therapy market include Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen Therapeutics, Ltd., and others.